Nanobiotix Shares Drop 4.32% Yet Hold a Yearly Gain of +802%
Nanobiotix shares fell by 4.32% to €27.48 mid-session on Monday, after closing at €28.72. The decline is part of a broader dip, with the CAC 40 down by 0.54% at 8,070.81 points. Despite this, the French biotech company maintains a one-year performance of 802%.
The Stock Moves Away from the €29.35 Resistance
The stock price now stands at €27.48, in the upper half of the Bollinger Bands ranging between €24.92 and €29.33. The identified resistance at €29.35, previously mentioned at the end of April in an earlier analysis, has not been surpassed in recent sessions. The RSI at 55 remains neutral and does not indicate a clear directional signal. The technical support is located at €25.25, approximately 8% below the current price. The 50-day moving average at €26.32 is slightly below the current price, while the 200-day moving average at €17.34 reflects the significant upward journey over the past twelve months.
Recent Trajectory Still Characterized by High Volatility
Over the past three months, the stock has still gained 50.49%, despite a weekly decline limited to 2.28%. The recent phase remains influenced by the scientific announcements made in April, including the presentation of preclinical data on the nanoprimer platform at the AACR conference. The market context remains cautious. The ECB kept its key interest rates unchanged on April 30, while simultaneously signaling heightened risks to both inflation and growth. Among other healthcare stocks on the Paris exchange, Sanofi is down 1.54% and Eurofins Scientific has lost 2.07% in the session. The next technical level to watch is the lower Bollinger boundary at €24.92, should the decline continue.
